Published in AIDS Weekly, February 9th, 2004
CYT 99 007 is a recombinant human Interleukin-7 developed by Cytheris. This cytokine targets the immune reconstitution of immuno-compromised patients, undergoing cancer treatment, affected by AIDS, or recovering from a bone marrow transplant.
This first phase I is performed in Bethesda, Maryland, in cooperation with National Cancer Institute investigators. The clinical trial, including oncology patients, will evaluate the safety, the immune effects, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.